Shingrix Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Herpes zoster vaccine (non-live recombinant, AS01_B adjuvanted)

Indications/Uses

Prevention of herpes zoster (HZ) & post-herpetic neuralgia (PHN) in adults ≥50 yr; & ≥18 yr at increased risk of HZ.

Dosage/Direction for Use

IM Primary vaccination 2 doses of 0.5 mL each, an initial dose followed by 2nd dose 2-6 mth later. Patient who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, & whom would benefit from shorter vaccination schedule 2nd dose can be given 1-2 mth after initial dose.

Contraindications

Hypersensitivity.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BK - Varicella zoster vaccines ; Used for active immunizations.

Regulatory Classification

POM

Presentation/Packing

Form

Shingrix powd & susp for susp for inj 50 mcg/0.5 mL

Packing/Price

1's

Shingrix

recombinant varicella-zoster virus glycoprotein e antigen vaccine

Manufacturer:

GlaxoSmithKline Biologicals